Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1 year

The purpose of this study is to identify the factors that require arthroplasty due to the progression of joint destruction, even when an anti-tumor necrosis factor (TNF) biological agent is used for rheumatoid arthritis (RA). Among 91 cases that used the anti-TNF biological agent for more than 1 yea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Modern rheumatology 2009, Vol.19 (4), p.390-394
Hauptverfasser:	Sano, Hiroshige, Arai, Katsumitsu, Murai, Takehiro, Fujisawa, Junichi, Kondo, Naoki, Netsu, Takahiro, Hanyu, Tadamasa, Saeki, Takako, Ito, Tomoyuki, Endo, Naoto
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - pathology Arthritis, Rheumatoid - physiopathology Arthroplasty Disease Progression Drug therapy Drug Therapy, Combination Etanercept Female Humans Immunoglobulin G - therapeutic use Infliximab Joint surgery Joints - drug effects Joints - pathology Joints - physiopathology Male Medicine Medicine & Public Health Methotrexate - therapeutic use Middle Aged Original Article Orthopedics Prospective Studies Receptors, Tumor Necrosis Factor - therapeutic use Rheumatoid arthritis Rheumatology Risk Factors Severity of Illness Index Tumor Necrosis Factor-alpha - antagonists & inhibitors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!